Cheap, Easy, and Lifesaving—Naloxone Treatment for Overdose

How much does it cost to save a life? That question got a clear and striking answer this week in the case of overdose from heroin in the United States. A study published in the Annals of Internal Medicine found that distribution of the overdose antidote naloxone—a safe, non-abusable, and inexpensive medicine—to one in five heroin users in the United States could prevent as many as 43,000 deaths. The cost of distribution would be equivalent to some of the cheapest, most effective, and most accepted medical interventions, like checking blood pressure at a doctor’s office.

The study used mathematical modeling to assess whether giving out naloxone was “worth it”—that is, to determine how much naloxone distribution would cost per “quality-adjusted” year of life gained. This is the measure used by economists and policymakers to compare health interventions and decide which ones are affordable. The naloxone study also investigated assumptions that patient advocates would rather not acknowledge—like whether it would be cheaper to let illegal drug users die, or to put them in jail. Those are ugly questions, but ones that certainly run through the minds of opponents of health services for drug users worldwide. The answer was that naloxone saves lives with costs far below what health or prison systems pay. For example, screening for cancer with colonoscopy costs over $50,000 per quality adjusted life year gained in the United States, and screening for HIV costs around $40,000.

Naloxone distribution saves lives for as little as $400.

The other question, of course, is whose lives are deemed worth saving. Drug overdose now kills more adults a year in the United States than motor vehicle accidents, or deaths from choking or accidental falls. Most of us have seen safety messages related to driving, choking, or minding our step, but naloxone and other measures to prevent overdose remain unknown to many at risk. As noted in an editorial in the same journal, co-authored by officials from the National Institute on Drug Abuse and the FDA, making new and easy-to-use formulations of the medicine can help. However, action can be taken now to make the medicine available to heroin users—actions that will prevent thousands of needless deaths, and spare family and friends who may have to watch helplessly as their loved ones stop breathing.

– Daniel Wolfe

Daniel Wolfe is director of the International Harm Reduction Development Program at the Open Society Foundations. This blog post was originally published on the Open Society Foundations website.


About CDPC

We are an independent civil society network of organizations and individuals working to improve Canada’s drug policies. Staff occasionally re-post important articles and curate this space with guest bloggers from our network.

Sign up for latest news and updates

MEDIA ADVISORY: Public forum to look at models... May 6, 2019

Going beyond decriminalization and envisioning a post-prohibition Canada where substances are legal and regulated What: Community forum featuring an international panel of experts on drug policy and experts with lived…

National Day of Action on the Overdose Crisis... April 18, 2019

Hundreds of supporters and community members converged in downtown Vancouver to send a message to policymakers. Prohibition is costing lives and safe supply is urgently needed.


From October 3 – 5, 2018, advocates and those inspired to create new approaches to drugs will be together in Edmonton, AB. This has been a CDPC vision for a long time….


This is a guest blog provided by Nazlee Maghsoudi. The Canadian Drug Policy attended HR17 and we are pleased to share this account of the conference. INCREASING INTERNATIONAL INTEREST IN DRUG…

insite vigil poem by the late Bud Osborn March 1, 2017

Last week, for the National Day of Action for the Overdose Crisis, we marched with 922 feathers, one for every life lost in BC in 2016. Our Executive Director, Donald MacPherson,…

In Memory of Raffi Balian February 22, 2017

Raffi Balian passed away on February 16, 2017 Raffi was one of the founding members of the Canadian Drug Policy Coalition (CDPC). He was very excited that the founding group…